Is your compound actually Therapeutic?
CETSA (Cellular Thermal Shift Assay)
The patented Cellular Thermal Shift Assay (CETSA®) gives a quantitative measure of target engagement and a true physiologically relevant readout of affinity, adding real value to existing efficacy assays. CETSA provides a measure for target engagement, which will help you make the right decisions faster and improve the quality in your discovery programs.
Who we are
Pelago Bioscience AB was founded in 2013 by the inventors and patent holders of Cellular Thermal Shift Assay (CETSA®) to provide and develop CETSA. The primary goal of Pelago is to change the field of drug discovery. We believe that when implemented on appropriate targets at an early stage CETSA can significantly reduce pre-clinical drug discovery timelines and reduce the risk of clinical stage failures. Better, safer, sooner drugs; that’s the goal of Pelago…
What we do
The Cellular Thermal Shift Assay (CETSA®) measures target engagement under actual physiological conditions, without the need to generate modified cell lines. It can be applied against known targets of interest to confirm actual potency both in model systems and patient derived material. Alternatively, it can be applied in a proteome wide approach that enables unknown targets of a compound to be identified.